Racial differences in the expression of transforming growth factor-beta 1 (TGF-beta 1) and caveolin-1, as well as differences in the expression of hepatocyte growth factor and PPAR-gamma, have been demonstrated in blacks with SSc, as well as in normal black individuals.
A genetic predisposition to fibrosis may account for much of the racial disparities between black and white patients with SSc.
Summary
A better understanding of the biologic basis for the racial disparities observed in SSc may lead to improved selleckchem therapies, along with the recognition that different therapies may need to be adapted for different groups of patients.”
“Current treatment modalities for soft tissue defects caused by various pathologies and trauma include autologous grafting and commercially available fillers. However, these treatment methods present a number of challenges and limitations, such as donor-site morbidity and volume loss over time. As such, improved therapeutic Fosbretabulin cell line modalities need to be developed. Tissue engineering techniques offer novel solutions to these problems through development of bioactive tissue constructs that can regenerate adipose tissue in both structure and function. Recently, a number of studies have been designed to explore various methods to engineer human adipose tissue. This review
will focus on these developments in the area of adipose tissue engineering for soft tissue replacement. The physiology of adipose tissue and current surgical therapies used to replace lost tissue volume, specifically in breast tissue, are introduced, and current biomaterials, cell sources, and tissue culture strategies are discussed. We discuss future areas of study in adipose tissue engineering.”
“Purpose of review
Lipid mediators including the lysophospholipids, Dactolisib sphingolipids and eicosanoids have long been implicated in inflammation, cancer and numerous other diseases. Over the last decade, new research suggests a role for these mediators in fibrosis.
Recent findings
Recent developments in the study of fibrotic mediators have centered
on lysophospholipids and eicosanoids. New research is evaluating metabolic-profiling strategies to quantitatively measure lipid mediators in human plasma. Lysophosphatidic acid receptor antagonists are currently under development with early phase trials scheduled for idiopathic pulmonary fibrosis and scleroderma dermal fibrosis. Eicosanoids have long been implicated in maintaining tissue homeostasis, and the balance of profibrotic and antifibrotic effects has drawn attention in recent years. Targeting the prostanoids, specifically PGE(2) and PGI(2), as well as the leukotrienes is now being considered for antifibrotic therapies.
Summary
Lipid mediators have significant roles in many disease processes.